Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability And Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-2 Product Definitions And Scope Of Study I-3 Cytotoxic Therapies I-3 Targeted Therapies I-3 II. EXECUTIVE SUMMARY 1. Industry Overview II-1 A Curtain Raiser II-1 Table 1: New Cases of Colorectal Cancer Diagnosed in the US for 2003-2006 (includes corresponding Graph/Chart) II-1 Table 2: Mortality Due to Colorectal Cancer in North America (2000-2003)-Breakdown by Region-United States, Canada and Mexico (includes corresponding Graph/Chart) II-2 Table 3: Mortality Due to Colorectal Cancer in Latin America (2000-2003)-Breakdown by Region-Brazil, Argentina, Venezuela, Peru, and Chile (includes corresponding Graph/Chart) II-2 Table 4: Mortality Due to Colorectal Cancer in Asia-Pacific (2000-2003)-Breakdown by Region-China, Japan, India, Indonesia, Philippines, Australia, Thailand, South Korea, Malaysia, Hong Kong, New Zealand, Singapore and Taiwan (includes corresponding Graph/Chart) II-3 Table 5: Mortality Due to Colorectal Cancer in Western Europe (2000-2003)-Breakdown by Region-Belgium, Austria, Denmark and Finland (includes corresponding Graph/Chart) II-3 Table 6: Staged Incidence of Cancer in the US by Race/ Ethnicity: (1992-2000) (includes corresponding Graph/Chart) II-4 Why Screening Rate is Low in Colorectal Cancer? II-4 Strategies to Increase Screening Rate II-5 Early Screening & Detection- A Antidotes to Beat the Odds II-5 Test at Home II-5 Breakdown of Colorectal Cancer Cases Based on the Risk Category II-6 Guidelines for Screening & Surveillance For Early Detection of Colorectal Cancer II-6 Who is at a Greater Risk of Developing Colorectal Cancer? II-7 Genetic Disposition II-7 Table 7: Selected Risk Factors and their Relative Risk Percentage in Colorectal Cancer (includes corresponding Graph/Chart) II-7 Happy Days are Here Again II-8 Table 8: Five Year Disease -Free Survival Rate of Various Cancers by Type- Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, and Malignant Melanoma (includes corresponding Graph/Chart) II-8 An Insight into Colorectal Cancer Therapeutic Alternatives II-9 2. Market Pulse II-10 Is Huge Cost of Drugs a Major Concern? II-10 Price Comparisons Among Leading Cancer Drugs Currently Available II-10 Is Cytotoxic Therapy Heading Towards the Sunset? II-10 An Insight into Cytotoxic Drugs Available in the US Colorectal Cancer Market II-11 Expiry Period of Leading Cytotoxic Drugs- Camptosar, Eloxatin, and Xeloda II-11 5-FU Struggling to Hold Share II-11 Xeloda on a Rise with Growing Indications II-11 Ongoing Phase III Clinical Trials to Evaluate Efficacy of Xeloda in Colorectal Cancer II-12 Edotecarin-An Evolving Cytotoxic Therapy II-12 Targeted Therapies-All Set to Stake a Claim Over the Future II-12 Avastin- The Wonder Drug II-13 Table 9: Key Parameters that Promote use of Avastin (includes corresponding Graph/Chart) II-13 PTK787 (vatalanib) II-13 ABX-EGF II-14 Targeted Therapies Add Value to Treatment Strategies II-14 Panitumumab- A Key Contender to Erbitux II-14 PTK787 v/s Avastin- Serious Warfare II-15 Combination Therapy- Offering a Lucrative Option II-15 A Peek into Standard Combination Therapies in Colorectal Cancer and their Status II-15 Reoccurrence of Cancer -A Prime Concern II-16 Table 10: Revenues from Adjuvant Colorectal Cancer Therapies in the US 2004-2007 (In US$ Million) (includes corresponding Graph/Chart) II-16 Table 11: Number of Colorectal Cancer Patients in Adjuvant Settings in the US: 2001-2007 (includes corresponding Graph/ Chart) II-16 Adjuvant Therapy in Colon Cancer II-17 Adjuvant Therapy in Rectal Cancer II-17 Colorectal Cancer Drugs in Adjuvant Settings II-17 3. Clinical Trials II-18 Prominent Products Still in Pipeline II-18 A Snapshot of Potential Drugs in the Pipeline II-18 4. Clinical Studies II-20 Adapalene (CD271) Retinoid Agent Induces Apoptosis in Colon Cancer Cells II-20 Laparoscopic Surgery Vs Open Surgery II-20 Discontinuation of Chemotherapy Drugs Raises the Chances of Reoccurrence II-20 Colorectal Cancer and Natural Substances II-20 Magnesium II-20 Vitamin D Protects Development of Tumor in Colon II-21 High Intake of Vitamin B Reduces Risk in Women II-21 Diet Rich in Flavonoids Fights Well Against Colorectal Cancer II-21 Colorectal Cancer and Other Medications II-21 NSAIDs Reduce the Risk of Colorectal Cancer II-21 Efficacy of Cancer Vaccine, ALVAC-CEA/B7.1, in Colorectal Cancer II-21 Insulin Therapy in type 2 Diabetic Patients Increases Risk II-22 5. Product Overview II-23 Colorectal Cancer-An Insight II-23 Colorectal Cancer . What is it .!!! II-23 What are the Symptoms? II-23 Risk Factors II-24 Selected General Risk Factors and their Relative Risk Rate in Colorectal Cancer II-24 Screening and Treatment II-25 Screening Options II-25 Digital Rectal Examination (DRE) II-25 Fecal Occult Blood Test II-25 Flexible Sigmoidoscopy II-25 Barium Enema II-25 Colonoscopy II-25 Additional Screening Options Of Recent Origin II-25 DNA-based Stool Test II-25 Virtual Colonoscopy II-26 A Comparative Analysis of Various Colorectal Cancer Screening Options Based on Parameters Such as Complexity, Risk Element, Potential Effectiveness, Overall Performance and Significant Limitations II-26 Appropriate Time Frame for Screening and Surveillance of Colorectal Cancer for Both Women and Men in the Age Group of 50 or More II-26 Supportive Diagnostic Tests II-27 Diagnosis/Treatment Options II-27 Partial Colectomy II-27 Chemotherapy II-27 Surgery II-27 Radiation Therapy II-27 A Structural Analysis of Available Treatment Options in Colorectal Cancer II-28 Staging II-28 Colorectal Cancer Therapies-At a Glance II-29 Cytotoxic Therapies II-29 5-FU (Fluorouracil) II-29 Camptosar (Irinotecan) II-29 Eloxatin (Oxaliplatin) II-29 Xeloda (Capecitabine) II-30 Targeted Therapies II-30 Angiogenesis Pathway II-30 Avastin (bevacizumab) II-31 EGF Pathway II-31 Erbitux (cetuximab) II-31 Cell Proliferation/Apoptosis II-32 Immune Response II-32 Cancer Vaccines II-32 Monoclonal Antibodies & their Function II-32 An Insight into the Targeted Therapies II-33 A Synoptic Review of Available Drugs Indicated in Treating Colorectal Cancer II-33 6. Product Approvals /Launches II-34 Chugai Applies for Quick Approval of Avastin in Japan II-34 Genentech Obtains FDA Approval for Avastin in Combination Therapy II-34 US FDA Approves Adjuvant Status for Roche’s Oral Xeloda II-34 Antisoma’s AS 1404 and Avastin Combination Therapy Proves Effective in Colon and Lung Cancer II-35 ImClone Systems and Bristol-Myers Squibb Receive Approval for Erbitux® Injection II-35 John Hopkins Develops Colorectal Cancer Blood Test Jointly with Howard Hughes Medical Institute and Indivumed II-35 Genentech Receives FDA Approval for Avastin II-35 Oxford BioMedica Gains Approval for Phase II Trial of TroVax® II-36 Roche’s Xeloda Gets Clearance as First-Line Colorectal Cancer Treatment II-36 LabCorp Introduces DNA-based Colorectal Cancer Test II-36 7. Recent Industry Activity II-37 Amgen Acquires Abgenix II-37 Chiron Merges with Novartis II-37 Bayer to Acquire Schering AG II-37 Biosite Collaborates with Oxford Genome II-37 Medarex Collaborates with Oxford Genome Sciences II-37 Pharmexa Acquires GemVax II-38 AstraZeneca to Acquire KuDOS Pharmaceuticals II-38 Aphton Corporation Acquires Igeneon II-38 IDM S.A. and Epimmune Merge to Form IDM Pharma II-38 Hybridon Renamed as Idera Pharmaceuticals II-38 Merck KGaA Acquires Rights for Taiho Pharmaceutical’s UFT II-38 Novartis and Schering Co-Promote PTK787/ZK 222584 Cancer Drug II-38 TWTI and Genzyme Genetics Set Up a Marketing Association II-39 Callisto Receives Patent for its Colon Cancer Drug II-39 Amgen and Abgenix Receive FDA Approval for Panitumumab in Metastatic Colorectal Cancer II-39 ADVENTRX Receives MHRA Approval to Initiate Phase IIb Clinical Trial II-39 Sanofi Acquires Aventis to Form Sanofi-Aventis II-39 8. Focus on Select Players II-40 Amgen Inc. (USA) II-40 Bristol-Myers Squibb (USA) II-40 F.Hoffmann-La Roche Ltd. (Switzerland) II-40 Genentech, Inc. (USA) II-40 Imclone Systems Inc. (USA) II-41 Novartis AG (Switzerland) II-41 Oxford Biomedica (UK) II-41 Pfizer Inc. (USA) II-41 Sanofi-Aventis (France) II-42 Schering AG (Germany) II-42 9. Global Market Perspective II-43 Table 12: World Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-43 Table 13: World 10-Year Perspective for Colorectal Cancer Therapies by Geographic Region/Country Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010 II-43 Table 14: World Recent Past, Current & Future Analysis for Cytotoxic Therapies for Colorectal Cancer by Geographic Region/Country United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-44 Table 15: World 10-Year Perspective for Cytotoxic Therapies for Colorectal Cancer by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010 II-44 Table 16: World Recent Past, Current & Future Analysis for Camptosar in Colorectal Cancer by Geographic Region/ Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-45 Table 17: World 10-Year Perspective for Camptosar in Colorectal Cancer by Geographic Region/ Country Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010 II-45 Table 18: World Recent Past, Current & Future Analysis for Eloxatin in Colorectal Cancer by Geographic Region/ Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-46 Table 19: World 10-Year Perspective for Eloxatin in Colorectal Cancer by Geographic Region/ Country Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010 II-46 Table 20: World Recent Past, Current & Future Analysis for Xeloda in Colorectal Cancer by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding graph/chart) II-47 Table 21: World 10-Year Perspective for Xeloda in Colorectal Cancer by Geographic Region/Country Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010 II-47 Table 22: World Recent Past, Current & Future Analysis for Targeted Therapies for Colorectal Cancer by Geographic Region/Country United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart) II-48 Table 23: World 6-Year Perspective for Targeted Therapies for Colorectal Cancer by Geographic Region/Country Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010 II-48 Table 24: World Recent Past, Current & Future Analysis for Avastin in Colorectal Cancer by Geographic Region/ Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart) II-49 Table 25: World 6-Year Perspective for Avastin in Colorectal Cancer by Geographic Region/Country Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010 II-49 Table 26: World Recent Past, Current & Future Analysis for Erbitux in Colorectal Cancer by Geographic Region/ Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart) II-50 Table 27: World 6-Year Perspective for Erbitux in Colorectal Cancer by Geographic Region/Country Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010 II-50 III. MARKET 1. US III-1 A.Market Analysis III-1 Introduction III-1 Market Accelerators III-1 Market Challenges III-1 Market Inhibitors III-1 Why Cost of Cancer Drugs is Too High in the US? III-1 Free-market Healthcare System- “For” & “Against” III-2 Erbitux- Making a Way Through the Colorectal Cancer Market III-2 Erbitux-A Blockbuster Drug in Third-Line Therapy III-2 Erbitux Enters the Genre of Second-Line Therapies III-3 Who Leads the Pack? III-3 Sanofi-Aventis- The Clear Leader III-3 Table 28: US Colorectal Cancer Market (2004): Percentage Breakdown of Leading Players-Sanofi-Aventis, Genentech, Pfizer, ImClone Systems/Bristol Myers-Squibb, Roche, and Generic Manufacturers-Ranked by Revenue (includes corresponding Graph/Chart) III-3 Table 29: US Colorectal Cancer Market for Cytotoxic Therapies (2004): Percentage Breakdown of Leading Players -Sanofi-Aventis, Pfizer, Roche and Generic Manufacturers- Ranked by Revenue (includes corresponding Graph/Chart) III-4 Table 30: US Colorectal Cancer Market for Targeted Therapies (2004): Percentage Breakdown of Leading Players -Genentech and ImClone Systems/Bristol Myers-Squibb- Ranked by Revenues III-4 Crucial Statistics III-4 Table 31: Incidence of Colorectal Cancer in the US (2006 )-Breakdown by Stages (includes corresponding Graph/Chart) III-4 Table 32: US Colorectal Cancer Statistics for 2004 & 2003 (includes corresponding Graph/Chart) III-4 Table 33: New Cases of Colorectal Cancer in the US for the years 2005 & 2006-Breakdown by Cancer Type III-5 Table 34: New Colorectal Cancer Cases in the US in 2004 & 2003-Breakdown by Type & Gender III-5 Product Approvals/Launches III-5 Strategic Developments III-7 Focus on Select Players III-8 B.Market Analytics III-9 Table 35: US Recent Past, Current & Future Analysis For Colorectal Cancer Therapeutics By Product Segments- Cytotoxic Therapies (5-Fu, Camptosar, Eloxatin And Xeloda) And Targeted Therapies (Avastin And Erbitux) Markets Independently Analyzed With Annual Sales In Us$ Million For Years 2001 Through 2010 (includes corresponding Graph/ Chart) III-9 Table 36: US 10-Year Perspective For Colorectal Cancer Therapeutics By Product Segments Percentage Breakdown Of Dollar Sales For Cytotoxic Therapies (5-Fu, Camptosar, Eloxatin And Xeloda) And Targeted Therapies (Avastin And Erbitux) For Years 2001, 2006 And 2010 (includes corresponding Graph/Chart) III-10 2. Rest of World III-11 A.Market Analysis III-11 Focus on Select Countries III-11 Canada III-11 Incidence III-11 Vital Statistics III-11 Table 37: Canadian Cancer Market (2005): Percentage Breakdown of New Cancer Cases Among Men (includes corresponding Graph/Chart) III-11 Table 38: Canadian Cancer Market (2005): Percentage Breakdown of Cancer Mortality Among Men (includes corresponding Graph/Chart) III-11 Table 39: Canadian Cancer Market (2005): Percentage Breakdown of New Cancer Cases Among Women (includes corresponding Graph/Chart) III-11 Table 40: Canadian Cancer Market (2005): Percentage Breakdown of Cancer Mortality Among Women (includes corresponding Graph/Chart) III-12 Table 41: New Colorectal Cancer Cases in Canada in 2005- By Gender III-12 Table 42: New Colorectal Cancer Cases in Canada in 2005- Breakdown By Age Group (includes corresponding Graph/ Chart) III-12 Table 43: Colorectal Cancer Mortality Statistics in Canada in 2005-Ranked By Gender III-12 Table 44: Colorectal Cancer Mortality Statistics in Canada in 2005-Breakdown By Age Group (includes corresponding Graph/Chart) III-13 Table 45: Incidence of Colorectal Cancer Among Men in Canada-By Region: 2005 (includes corresponding Graph/ Chart) III-13 Table 46: Incidence of Colorectal Cancer Among Women in Canada-By Region: 2005 (includes corresponding Graph/ Chart) III-13 Finland III-14 Overview III-14 Active Screening Programs- A Mission to Fight Against Cancer III-14 Product Approvals III-14 Strategic Developments III-15 Focus on Select Players III-17 B.Market Analytics III-19 Table 47: Rest of World Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Product Segments- Cytotoxic Therapies (Camptosar, Eloxatin and Xeloda) and Targeted Therapies (Avastin and Erbitux) Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/ Chart) III-19 Table 48: Rest of World 10-Year Perspective for Colorectal Cancer Therapeutics by Product Segments Percentage Breakdown of Dollar Sales for Cytotoxic Therapies (Camptosar, Eloxatin and Xeloda) and Targeted Therapies (Avastin and Erbitux) for Years 2001, 2006 and 2010 (includes corresponding Graph/Chart) III-19 IV. COMPETITION 1. Abbott Laboratories (USA) IV-1 Table 49: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-3 Table 50: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-3 Table 51: Half Yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ million) IV-4 Table 52: Annual Sales Analysis: 2003-2005 (In US$ million) IV-4 Table 53: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-4 Table 54: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million) IV-4 Table 55: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-5 2. Adherex Technologies, Inc. (USA) IV-14 3. Adventrx Pharmaceuticals, Inc. (USA) IV-16 4. Amgen, Inc. (USA) IV-18 Table 56: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-19 Table 57: Half Yearly Sales Analysis by Segment: 2005- 2006 (H1) (In US$ million) IV-19 Table 58: Annual Sales Analysis: 2004-2005 (In US$ million) IV-19 Table 59: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-19 Table 60: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-19 5. AnorMed, Inc. (Canada) IV-22 Table 61: Annual Sales Analysis: 2004-2006 (In Can$ million) IV-22 6. Antigenics, Inc. (USA) IV-24 Table 62: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-25 Table 63: Half Yearly Sales Analysis by Quarter: 2005- 2006 (H1) (In US$ million) IV-25 Table 64: Annual Sales Analysis: 2003-2005 (In US$ million) IV-25 7. Aphton Corporation (USA) IV-28 8. Arius Research, Inc. (Canada) IV-31 Table 65: Annual Sales Analysis: 2004-2005 (In Can$ million) IV-31 9. Astellas Pharma US, Inc. (USA) IV-33 10. Astrazeneca PLC (UK) IV-35 Table 66: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-37 Table 67: Half Yearly Sales Analysis by Quarter: 2005- 2006 (H1) (In US$ million) IV-37 Table 68: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million) IV-38 Table 69: Annual Sales Analysis: 2003-2005 (In US$ million) IV-38 Table 70: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-38 Table 71: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-38 11. Avastin (USA) IV-47 12. AVI Biopharma, Inc. (USA) IV-48 Table 72: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousands) IV-49 Table 73: Half Yearly Sales Analysis by Quarter: 2005- 2006 (In US$ thousands) IV-49 Table 74: Annual Sales Analysis: 2003-2005 (In US$ thousands) IV-49 Table 75: Quarterly Sales Analysis: 2004-2005 (In US$ thousands) IV-49 13. Bayer HealthCare AG (Germany) IV-52 Table 76: Annual Sales Analysis: 2004-2005 (In € million) IV-54 Table 77: Annual Sales Analysis by Business Segment: 2004-2005 (In € million) IV-54 Table 78: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-54 14. Biomira, Inc. (Canada) IV-58 15. Biosite, Inc. (USA) IV-59 Table 79: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-60 Table 80: Annual Sales Analysis: 2004-2005 (In US$ million) IV-60 Table 81: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-60 16. BioStratum, Inc. (USA) IV-64 17. Boehringer Ingelheim GmbH (Germany) IV-65 Boehringer Ingelheim Corporation (USA) IV-69 18. Bristol-Myers Squibb Company (USA) IV-71 Table 82: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-73 Table 83: Half Yearly Sales Analysis by Quarter: 2005- 2006 (H1) (In US$ billion) IV-73 Table 84: Half Yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ billion) IV-73 Table 85: Annual Sales Analysis: 2003-2005 (In US$ billion) IV-73 Table 86: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion) IV-73 Table 87: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ billion) IV-74 Table 88: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-74 19. Callisto Pharmaceuticals, Inc. (USA) IV-79 20. ChemGenex Pharmaceuticals Ltd. (Australia) IV-83 Table 89: Annual Sales Analysis: 2004-2005 (In US$ thousands) IV-84 21. Dendreon Corporation (USA) IV-86 Table 90: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-86 Table 91: Annual Sales Analysis: 2004-2005 (In US$ million) IV-86 Table 92: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-87 Eisai, Inc. (USA) IV-88 22. Eli Lilly & Company (USA) IV-90 Table 93: Annual Sales Analysis: 2003-2005 (In US$ million) IV-92 23. F. Hoffmann-La Roche Ltd. (Switzerland) IV-97 Table 94: First Quarter Sales Analysis: 2005-2006 (In CHF billion) IV-98 Table 95: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion) IV-98 Table 96: Annual Sales Analysis: 2003-2005 (In CHF billion) IV-98 Roche Laboratories, Inc. (USA) IV-101 Chugai Pharmaceutical Co., Ltd. (Japan) IV-101 Table 97: First Quarter Sales Analysis: 2005-2006 (In ¥ million) IV-102 Table 98: Annual Sales Analysis: 2004-2005 (In ¥ million) IV-102 24. Gemin X Biotechnologies, Inc. (Canada) IV-105 25. Genentech, Inc. (USA) IV-106 Table 99: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-108 Table 100: Annual Sales Analysis: 2004-2005 (In US$ million) IV-108 Table 101: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-108 26. Genvec, Inc. (USA) IV-113 Table 102: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-114 Table 103: Annual Sales Analysis: 2004-2005 (In US$ million) IV-114 27. Genzyme Corporation (USA) IV-119 Table 104: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-122 Table 105: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million) IV-122 Table 106: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ million) IV-123 Table 107: Annual Sales Analysis: 2004-2005 (In US$ million) IV-123 Table 108: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-123 Table 109: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-123 Table 110: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-124 28. Glaxosmithkline PLC (UK) IV-129 Table 111: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ million) IV-130 Table 112: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In £ million) IV-130 Table 113: Annual Sales Analysis: 2004-2005 (In £ million) IV-130 Table 114: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-130 GlaxoSmithKline, Inc. (USA) IV-139 29. Glycogenesys, Inc. (USA) IV-142 30. Idera Pharmaceuticals, Inc. (USA) IV-143 31. IDM Pharma, Inc. (USA) IV-144 Table 115: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-144 Table 116: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million) IV-144 Table 117: Annual Sales Analysis: 2004-2005 (In US$ million) IV-145 32. ImClone Systems, Inc. (USA) IV-146 Table 118: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-147 Table 119: Annual Sales Analysis: 2003-2005 (In US$ million) IV-147 Table 120: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-148 33. Immunomedics, Inc. (USA) IV-150 Table 121: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million) IV-151 Table 122: Nine Months Sales Analysis by Geographic Region: 2005-2006 (Nine Months Ended, March) (In US$ million) IV-151 Table 123: Annual Sales Analysis: 2004-2005 (In US$ million) IV-151 Table 124: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-151 34. Indivumed GmbH (Germany) IV-153 35. Intracel (USA) IV-154 36. Introgen Therapeutics, Inc. (USA) IV-155 Table 125: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-156 Table 126: Annual Sales Analysis: 2003-2005 (In US$ million) IV-156 37. Ivax Corporation (USA) IV-159 Table 127: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-162 Table 128: Nine Months Sales Analysis by Quarter: 2004 -2005 (Nine Months Ended, September) (In US$ billion) IV-162 Table 129: Nine Months Sales Analysis by Product: 2004 -2005 (Nine Months Ended, September) (In US$ billion) IV-162 Table 130: Nine Months Sales Analysis by Geographic Region: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-162 38. Johnson & Johnson Pharmaceutical Research & Development LLC (USA) IV-169 39. Lorus Therapeutics (Canada) IV-171 40. Medarex, Inc. (USA) IV-174 Table 131: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-175 Table 132: Annual Sales Analysis: 2003-2005 (In US$ million) IV-175 Table 133: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-175 41. MediGene AG (Germany) IV-179 Table 134: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-179 42. Medimmune, Inc. (USA) IV-181 Table 135: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-182 Table 136: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million) IV-182 Table 137: Half Yearly Sales Analysis by Operation: 2006-2005 (In US$ IV-183 Table 138: Annual Sales Analysis: 2003-2005 (In US$ million) IV-183 Table 139: Annual Sales Analysis by Operation: 2004- 2005 (In US$ million) IV-183 Table 140: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-183 43. Merck & Co., Inc. (USA) IV-186 Table 141: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-187 Table 142: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million) IV-187 Table 143: Half Yearly Sales Analysis by Product: 2005 -2006 (H1) (In US$ million) IV-187 Table 144: Annual Sales Analysis: 2003-2005 (In US$ million) IV-188 Table 145: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-188 Table 146: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-188 44. Merck KGaA (Germany) IV-193 Table 147: Annual Sales Analysis: 2004-2005 (In € million) IV-195 Table 148: Annual Sales Analysis Segment: 2004-2005 (In € million) IV-195 45. Millennium Pharmaceuticals, Inc. (USA) IV-199 Table 149: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-199 Table 150: Annual Sales Analysis: 2004-2005 (In US$ million) IV-199 Table 151: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-200 46. Myriad Genetics, Inc. (USA) IV-202 Table 152: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million) IV-203 Table 153: Nine Months Sales Analysis by Quarter: 2005 -2006 (Nine Months Ended, March) (In US$ million) IV-203 Table 154: Nine Months Sales Analysis by Segment: 2005 -2006 (Nine Months Ended, March) (In US$ million) IV-203 Table 155: Annual Sales Analysis: 2004-2005 (In US$ million) IV-203 Table 156: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-203 Table 157: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-204 47. Novartis AG (Switzerland) IV-205 Table 158: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-208 Table 159: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ million) IV-208 Table 160: Annual Sales Analysis: 2003-2005 (In US$ million) IV-209 Table 161: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-209 Table 162: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-209 Chiron Corporation (USA) IV-217 Table 163: Annual Sales Analysis: 2003-2005 (In US$ million) IV-219 Table 164: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-219 Table 165: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-220 Table 166: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-220 Novartis Pharmaceuticals Corporation (USA) IV-224 48. Onyx Pharmaceuticals, Inc. (USA) IV-229 Table 167: Annual Sales Analysis: 2004-2005 (In US$ million) IV-230 49. Ortho Biotech Products LP (USA) IV-231 50. OSI Pharmaceuticals (USA) IV-233 Table 168: Half Yearly Sales Analysis: 2005-2006 (In US$ million) IV-234 Table 169: Annual Sales Analysis: 2004-2005 (In US$ million) IV-234 51. Oxford Biomedica PLC (UK) IV-237 Table 170: Annual Sales Analysis: 2004-2005 (In £ million) IV-237 52. Oxford Genome Sciences (U.K.) Ltd. (UK) IV-241 53. Oxigene, Inc. (USA) IV-243 54. Pfizer, Inc. (USA) IV-245 Table 171: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-247 Table 172: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ billion) IV-247 Table 173: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion) IV-248 Table 174: Annual Sales Analysis: 2003-2005 (In US$ billion) IV-248 55. Pharmexa A/S (Denmark) IV-252 Table 175: Half Yearly Sales Analysis: 2005-2006 (H1) (In DKK million) IV-252 56. Sanofi-Aventis (France) IV-257 Table 176: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-258 Table 177: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In € million) IV-258 Table 178: Annual Sales Analysis: 2004-2005 (In € million) IV-258 Table 179: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-258 Table 180: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-259 Sanofi-Aventis (USA) IV-264 57. Schering AG (Germany) IV-266 Table 181: First Quarter Sales Analysis: 2005-2006 (In € billion) IV-267 Table 182: First Quarter Sales Analysis by Segment: 2005-2006 (In € billion) IV-267 Table 183: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In € billion) IV-268 Table 184: Annual Sales Analysis: 2003-2005 (In € billion) IV-268 Table 185: Annual Sales Analysis by Segment: 2004-2005 (In € billion) IV-268 Table 186: Annual Sales Analysis by Geographic Region: 2004-2005 (In € billion) IV-268 Schering-Plough Corporation (USA) IV-273 Table 187: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-274 Table 188: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ million) IV-274 Table 189: Annual Sales Analysis: 2004-2005 (In US$ million) IV-274 Table 190: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) (Germany)) IV-274 Table 191: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-275 Table 192: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-275 58. Supergen, Inc. (USA) IV-278 Table 193: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-279 Table 194: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million) IV-279 Table 195: Annual Sales Analysis: 2004-2005 (In US$ million) IV-279 59. Telik, Inc. (USA) IV-281 60. Therion Biologics Corporation (USA) IV-283 61. Third Wave Technologies, Inc. (USA) IV-284 Table 196: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-285 Table 197: Annual Sales Analysis: 2004-2005 (In US$ million) IV-285 62. Titan Pharmaceuticals, Inc. (USA) IV-287 Table 198: Annual Sales Analysis: 2004-2005 (In US$ million) IV-287 63. Topotarget A/S (Denmark) IV-289 Table 199: Annual Sales Analysis: 2004-2005 (In DKK million) IV-289 64. Transgene SA (France) IV-291 Table 200: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-291 Table 201: Annual Sales Analysis: 2004-2005 (In € million) IV-291 65. Viventia Biotech, Inc. (Canada) IV-293 66. Wyeth (USA) IV-294 Table 202: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-296 Table 203: Half Yearly Sales Analysis by Segment: 2006 -2005 (H1) (In US$ billion) IV-296 Table 204: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-296 Table 205: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-296 Table 206: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-296 67. Xoma (US) LLC (USA) IV-301 Table 207: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-301 Table 208: Annual Sales Analysis: 2004-2005 (In US$ million) IV-302 Table 209: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-302 68. YM Biosciences, Inc. (Canada) IV-305 Table 210: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In Can$ million) IV-305 Table 211: Annual Sales Analysis: 2004-2005 (In Can$ million) IV-305

Companies Mentioned

The Companies mentioned inside this report include: - Abbott Laboratories (USA) - Adherex Technologies, Inc (USA) - Adventrx Pharmaceuticals, Inc (USA) - Amgen, Inc (USA) - AnorMed, Inc (Canada) - Antigenics, Inc (USA) - Aphton Corporation (USA) - Arius Research, Inc (Canada) - Astellas Pharma US, Inc (USA) - Astrazeneca PLC (UK) - Avastin (USA) - AVI Biopharma, Inc (USA) - Bayer HealthCare AG (Germany) - Biomira, Inc (Canada) - Biosite, Inc (USA) - BioStratum, Inc (USA) - Boehringer Ingelheim GmbH (Germany) - Boehringer Ingelheim Corporation (USA) - Bristol-Myers Squibb Company (USA) - Callisto Pharmaceuticals, Inc (USA) - ChemGenex Pharmaceuticals Ltd (Australia) - Dendreon Corporation (USA) - Eisai, Inc (USA) - Eli Lilly & Company (USA) - F Hoffmann-La Roche Ltd (Switzerland) - Roche Laboratories, Inc (USA) - Chugai Pharmaceutical Co, Ltd (Japan) - Gemin X Biotechnologies, Inc (Canada) - Genentech, Inc (USA) - Genvec, Inc (USA) - Genzyme Corporation (USA) - Glaxosmithkline PLC (UK) - GlaxoSmithKline, Inc (USA) - Glycogenesys, Inc (USA) - Idera Pharmaceuticals, Inc (USA) - IDM Pharma, Inc (USA) - ImClone Systems, Inc (USA) - Immunomedics, Inc (USA) - Indivumed GmbH (Germany) - Intracel (USA) - Introgen Therapeutics, Inc (USA) - Ivax Corporation (USA) - Johnson & Johnson Pharmaceutical Research & Development LLC (USA) - Lorus Therapeutics (Canada) - Medarex, Inc (USA) - MediGene AG (Germany) - Medimmune, Inc (USA) - Merck & Co, Inc (USA) - Merck KGaA (Germany) - Millennium Pharmaceuticals, Inc (USA) - Myriad Genetics, Inc (USA) - Novartis AG (Switzerland) - Chiron Corporation (USA) - Novartis Pharmaceuticals Corporation (USA) - Onyx Pharmaceuticals, Inc (USA) - Ortho Biotech Products LP (USA) - OSI Pharmaceuticals (USA) - Oxford Biomedica PLC (UK) - Oxford Genome Sciences (UK) Ltd (UK) - Oxigene, Inc (USA) - Pfizer, Inc (USA) - Pharmexa A/S (Denmark) - Sanofi-Aventis (France) - Sanofi-Aventis (USA) - Schering AG (Germany) - Schering-Plough Corporation (USA) - Supergen, Inc (USA) - Telik, Inc (USA) - Therion Biologics Corporation (USA) - Third Wave Technologies, Inc (USA) - Titan Pharmaceuticals, Inc (USA) - Topotarget A/S (Denmark) - Transgene SA (France) - Viventia Biotech, Inc (Canada) - Wyeth (USA) - Xoma (US) LLC (USA) - YM Biosciences, Inc (Canada)